Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2007

View Archived Issues

Minocycline has positive effects on atherosclerotic plaques

J591 targets metastatic sites in patients with advanced solid tumors

InterMune focuses on programs for pirfenidone and ITMN-191

Terameprocol found effective in patients with oral leukoplakia

Phase I/II studies to investigate nab-docetaxel for prostate and breast cancers

Inex anticipates 2007 milestones

IL-21 benefits mice with melanoma

Transition Therapeutics to acquire NeuroMedix

ASKA and Yakult Honsha sign agreement for soblidotin

Arpida completes enrollment in iclaprim phase III program

EVT-302 for smoking cessation begins clinical testing

Enrollment completed in phase Ib cancer study of bavituximab

Merck & Co. licenses Japanese rights to Cubicin

Topigen and Novagali collaborate on allergic ocular diseases and allergic rhinitis

ProAlgaZyme to be studied in metabolic syndrome patients

Clomet studied in phase I for solid tumors

Amgen discontinues Vectibix treatment in PACCE trial

Trexima amended response accepted for review

CDC adopts ACIP's recommendations on use of Gardasil

UCB to begin new study on Cimzia in Crohn's disease

Bioavailability of cetrorelix in Japanese subjects similar to that in non-Japanese

Ambrisentan MAA validated by EMEA

Bosentan recommended for E.U. approval to reduce digital ulcers

CHMP recommends approval of Remicade for pediatric Crohn's disease

MK-0974 enters phase III program, NDA expected for 2009

Recent patents report novel therapeutic agents for the treatment of respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...